₹2,505.8
▼ -37.9 -1.49%
30 Jul 2026
NSE Listed · Pharmaceuticals
Gland Pharma Limited (GLAND)
Volume: 3,83,931Avg Vol 1W: 3,65,134Avg Vol 1M: 4,85,67152W Range:₹1,573.6₹2,586
Key Ratios
Checked just nowMarket Cap₹41,336 Cr
Current Price₹2,505.8
Previous Close₹2,543.7
High / Low (52w)₹2,586 / ₹1,573.6
Volume3,83,931
Avg Vol (1W)3,65,134
Avg Vol (1M)4,85,671
Stock P/E112.57
Book Value₹628.52
Dividend Yield0.88%
ROE9.92%
ROA8.21%
Revenue (TTM)—
Revenue Growth-0.85%
Profit Margin15.98%
Total Debt₹78 Cr
Shares Outstanding16 Cr
Face Value₹1
EPS (TTM)₹22.26
P/B3.99
Debt / Equity0.03
50 DMA₹2,362.04
200 DMA₹1,928.43
Day change-1.49%
Price Chart
₹2,505.8▲ 21.60% · 1Y
2025-07-302026-07-30
20-day avg volume: 4.8L shares
Pros
- Company is almost debt-free.
- Net profit is growing year over year.
Cons
- Stock trades at a high P/E of 113.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,402 Cr | ₹1,406 Cr | ₹1,384 Cr | ₹1,425 Cr | ₹1,506 Cr | ₹1,487 Cr | ₹1,695 Cr | ₹1,743 Cr |
| EBITDA | ₹224 Cr | ₹263 Cr | ₹322 Cr | ₹296 Cr | ₹324 Cr | ₹292 Cr | ₹390 Cr | ₹516 Cr |
| Net Profit | ₹144 Cr | ₹164 Cr | ₹205 Cr | ₹187 Cr | ₹215 Cr | ₹184 Cr | ₹261 Cr | ₹367 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,063 Cr | ₹1,011 Cr | ₹1,030 Cr | ₹5,830 Cr | ₹1,039 Cr | ₹1,074 Cr | ₹1,178 Cr | ₹1,262 Cr |
| EBITDA | ₹380 Cr | ₹412 Cr | ₹395 Cr | ₹1,105 Cr | ₹370 Cr | ₹413 Cr | ₹437 Cr | ₹571 Cr |
| Net Profit | ₹282 Cr | ₹295 Cr | ₹290 Cr | ₹699 Cr | ₹269 Cr | ₹302 Cr | ₹308 Cr | ₹420 Cr |
| EPS | — | — | — | 42.4 | — | — | — | — |
Balance Sheet
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Total Assets | ₹4,086 Cr | ₹6,496 Cr | ₹7,834 Cr | ₹8,778 Cr | ₹10,661 Cr | ₹11,225 Cr |
| Total Liabilities | ₹440 Cr | ₹593 Cr | ₹676 Cr | ₹819 Cr | ₹1,937 Cr | ₹2,074 Cr |
| Equity | ₹3,646 Cr | ₹5,903 Cr | ₹7,158 Cr | ₹7,959 Cr | ₹8,724 Cr | ₹9,151 Cr |
| Total Debt | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Operating | ₹945 Cr | ₹916 Cr | ₹1,197 Cr | ₹675 Cr | ₹1,303 Cr | ₹1,269 Cr |
| Investing | ₹-766 Cr | ₹-1,524 Cr | ₹-1,003 Cr | ₹1,208 Cr | ₹-1,757 Cr | ₹1,705 Cr |
| Financing | ₹-7 Cr | ₹1,238 Cr | ₹35 Cr | ₹15 Cr | ₹-799 Cr | ₹-433 Cr |
| Free Cash Flow | ₹945 Cr | ₹916 Cr | ₹1,197 Cr | ₹675 Cr | ₹1,303 Cr | ₹1,269 Cr |
Shareholding
Promoter 51.77% Institutions 39.18% Public 9.05%
Efficiency & Working Capital
ROCE15.8%
Interest Coverage26.3
Dividend Payout—
Debtor Days99 d
Inventory Days110 d
Payable Days53 d
Cash Conversion Cycle155 d
Working Capital Days208 d
Shareholding Details
As of 2026-06-30
Promoter51.8%
FII8.7%
DII30.4%
Institutions39.2%
Public9.1%
Promoter Pledge0%
No. of Shareholders1,08,266
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 57.9% | 57.9% | 57.9% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% |
| FIIs | 4.9% | 4% | 3.6% | 6.9% | 4.5% | 5% | 6.9% | 7.4% | 7.9% | 7.6% | 7.3% | 8.7% |
| DIIs | 22.4% | 23.1% | 25.2% | 32.8% | 35.4% | 34.8% | 33.3% | 32.9% | 32.6% | 33% | 33.4% | 30.4% |
| Public | 14.8% | 15% | 13.3% | 8.5% | 8.3% | 8.3% | 8% | 7.9% | 7.6% | 7.6% | 7.5% | 9.1% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 1,61,627 | 1,36,021 | 1,22,375 | 1,22,665 | 1,22,358 | 1,21,075 | 1,13,788 | 1,10,671 | 97,151 | 94,578 | 91,500 | 1,08,266 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Fosun Pharma Industrial Pte. Ltd | Shareholding of Promoter and Promoter Group | 51.8% | 8.54 Cr |
| Hdfc Mutual Fund - Hdfc Mid-cap Fund | Public Shareholding | 6.1% | 1.01 Cr |
| Mirae Asset Large & Midcap Fund | Public Shareholding | 5.7% | 93,78,765 |
| Nippon Life India Trustee Ltd- A/c Nippon India Growth Mid Cap Fund | Public Shareholding | 4.9% | 81,31,364 |
| Sbi Large & Midcap Fund | Public Shareholding | 3.3% | 54,84,673 |
| Icici Prudential India Opportunities Fund | Public Shareholding | 1.8% | 29,53,459 |
| Dsp Small Cap Fund | Public Shareholding | 1.6% | 26,76,014 |
| Government Pension Fund Global | Public Shareholding | 1.3% | 22,14,227 |
| Uti-flexi Cap Fund | Public Shareholding | 1.2% | 20,17,866 |
| Ample Up Limited | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Fosun Industrial Co Limited | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Lustrous Star Limited | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Regal Gesture Limited | Shareholding of Promoter and Promoter Group | 0% | 10 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| SRINIVAS SADU | Chairman / Executive Director / MD / CEO | 2025 |
| UDO JAHANNES VETTER | Independent Non Exe. Director | 2025 |
| ESSAJI GOOLAM VAHANVATI | Independent Non Exe. Director | 2025 |
| Jia Ai (Allen) Zhang | Non-Exec & Non-Independent Dir | 2025 |
| Naina Lal Kidwai | Independent Non Exe. Director | 2025 |
| Wenjie Zhang | Non-Exec & Non-Independent Dir | 2025 |
| Wei Huang | Non-Exec & Non-Independent Dir | 2025 |
| SAMPATH KUMAR PALLERLAMUDI | CS / Compliance Officer / Vice President | 2025 |
| William Robert Keller | Additional Director | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| USA | ₹2,128 Cr | 61.5% |
| India | ₹556 Cr | 16.1% |
| Europe | ₹151 Cr | 4.4% |
| Canada | ₹66 Cr | 1.9% |
| Australia | ₹16 Cr | 0.5% |
| Rest Of The World | ₹546 Cr | 15.8% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹1 | 50 | 16 | 16 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-11 | Dividend (20/- per share) | Final |
| dividend | 2026-08-11 | ₹20 (2000%) | Final |
| forthcoming | 2026-08-10 | Board Meetings | — |
| dividend | 2025-08-14 | ₹18 (1800%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 17,891 | 0 | 0 | 15 | 0 | 17,906 |
| 2025 | 404 | 0 | 0 | 0 | 0 | 404 |
| 2025 | 2,225 | 0 | 0 | 15 | 0 | 2,240 |
Insider / Designated-Person Trades
14 recent disclosure(s)
Jayatheerth AdvaniDisposal · 1,000
K RAGHURAMACHANDRA RAODisposal · 1,000
K RAGHURAMACHANDRA RAODisposal · 1,000
Jayatheerth AdvaniDisposal · 500
SREENIVASA RAO SURAGAMDisposal · 500
SREENIVASA RAO SURAGAMDisposal · 1,000
Substantial Acquisitions (SAST)
11 disclosure(s)
Market11/04/2025 · 4,00,020
Market24/06/2024 · 60,000
Market19/06/2024 · 99,00,000
Market27/05/2024 · 5,85,086
Market09/04/2024 · 33,75,525
Market09/04/2024 · 61,65,486
Company Information
🌐 www.glandpharma.com ↗
📍 Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad, Telangana, 500043
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Gujarat Industries Power Co Ltd.Giriraj Civil Developers Ltd.Grover Jewells LimitedGK Energy LimitedGujarat Kidney & Super Speciality Ltd.GKW LimitedGlaxosmithkline Pharmaceuticals Ltd.Glenmark Pharmaceuticals Ltd.Gujarat Lease Financing LimitedGlobal Education LimitedGlobale Tessile LimitedGlobal Pet Industries Ltd.All “G” stocks →
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search